Search results
Author(s):
Freek WA Verheugt
Added:
3 years ago
The yearly incidence of stroke in patients with atrial fibrillation (AF) is approximately 5%,1 which is five times higher than in comparable populations in sinus rhythm (SR). The stroke risk largely depends on the underlying heart disease. In 'lone' AF (absence of heart disease) the stroke risk is only 0.5% per year,2 whereas in AF associated with rheumatic valvular heart disease (VHD), like…
View more
Author(s):
Freek WA Verheugt
Added:
3 years ago
The yearly incidence of stroke in patients with atrial fibrillation (AF) is approximately 5%, which is five times higher than in comparable populations in sinus rhythm (SR). The stroke risk largely depends on the underlying heart disease. In 'lone' AF (absence of heart disease) the stroke risk is only 0.5% per year, whereas in AF associated with rheumatic valvular heart disease (VHD), like mitral…
View more
Author(s):
A John Camm
Added:
3 years ago
Atrial fibrillation(AF), a major cause of morbidity and mortality in the Western world, is considered to be a rising epidemic.1–3 In the US alone, approximately 2.7 million people are affected by AF4 and this figure is projected to increase to an estimated 16 million by 2050.5 The rising prevalence of AF is mainly attributable to the ageing population6 and survival from other cardiovascular…
View more
Author(s):
Gheorghe-Andrei Dan
,
Adrian Catalin Buzea
Added:
3 years ago
Non-antivitamin K oral anticoagulants (NOACs) are no longer ‘new’ drugs: they already are established. Since randomised controlled trials (RCTs) usually enrol highly selected patient populations, the best way to demonstrate new drug efficiency/cost-effectiveness is to use long-term and ‘real-world’ data. In order to understand the NOAC experience in real life properly, one must first understand…
View more
Author(s):
Paul Wang
Added:
1 year ago
AHA 22: Dr Paul Wang (Cardiac Arrhythmia Service at Palo Alto, Stanford, CA, US) joins us remotely to discuss the findings of the ENHANCE-AF trial, originally presented at the American Heart Association's 2022 Scientific Sessions.
ENHANCE AF aimed to evaluate whether a shared-decision-making pathway tool would reduce the risk of stroke as a result of atrial fibrillation when compared to standard…
View more
New Stroke Outcomes Data: The Role of Prolonged Cardiac Monitoring in Secondary Stroke Prevention
Author(s):
Wolfram Döhner
,
Georgios Tsivgoulis
,
Robert Hatala
Start date:
Oct 09, 2019
Broadcast
Author(s):
Andreas Müssigbrodt
,
Gerhard Hindricks
Added:
3 years ago
Abstract
After the release of the 2010 guidelines of the European Society of Cardiology (ESC) and the 2011 update of the guidelines of the American Heart Association/American College of Cardiology (AHA/ACC), new evidence has emerged that requires adaption of current clinical practice in the treatment of atrial fibrillation (AF). In 2011, results were published from two central AF trials…
View more
Author(s):
Massimo Volpe
,
Giuliano Tocci
,
Francesca Giovannelli
Added:
3 years ago
Cerebrovascular accidents are one of the leading causes of morbidity and mortality worldwide. The World Health Organization (WHO) found that in 1990 stroke accounted for 4.3 million mortalities, the third most common cause of death worldwide. Projecting forward to 2020, the incidence of stroke-related death is expected to rise to 7.7 million per year.
High blood pressure is one of the most…
View more
Author(s):
Mukul Sharma
Added:
1 year ago
ESC Congress 22 — We are joined onsite by Dr Mukul Sharma (Mcmaster University, CA) to discuss the findings of the AXIOMATIC-SSP (NCT03766581) trial.
This study aimed to evaluate the effectiveness of oral Factor XIa inhibitor milvexian in addition to aspirin and clopidogrel as compared to standard therapies in secondary stroke prevention. 2366 participants were involved in the trial, and were…
View more
Author(s):
Tri Huynh Quang Ho
,
Minh That Ton
,
Viet Lan Nguyen
,
et al
Added:
3 months ago